Leerink Partners Downgrades Fusion Pharmaceuticals (FUSN) to Market Perform
Tweet Send to a Friend
Leerink Partners analyst Faisal Khurshid downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
